Xenetic Biosciences
XBIO
9 hedge funds and large institutions have $724K invested in Xenetic Biosciences in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more capital invested
Capital invested by funds: $581K → $724K (+$143K)
13% more funds holding
Funds holding: 8 → 9 (+1)
0.01% more ownership
Funds ownership: 0.86% → 0.87% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$153K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$69.5K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$32.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$177K |
| 2 |
VF
Virtu Financial
New York
|
-$42K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $382K | -$177K | -13,905 | -34% |
|
|
2
Renaissance Technologies
New York
| $174K | +$153K | +12,080 | New |
|
|
OAM
3
Oxford Asset Management
Oxford,
United Kingdom
| $79K | +$69.5K | +5,475 | New |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $39K | – | – | – |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $36K | +$32.3K | +2,544 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $14K | +$8.88K | +699 | +252% |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $153 | – | – | – |
|
|
VF
8
Virtu Financial
New York
| – | -$42K | -3,506 | Closed |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$20K | -1,690 | Closed |
|
XBIO Hedge Fund Activity: Q4 2019 in Review
9 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2019, worth a combined $724K — up 25% from $581K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XBIO positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $153K. The largest seller was Sabby Management, cutting an estimated $177K.
- 9 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2019, up from 8 in Q3 2019.
- Funds reported $724K of Xenetic Biosciences stock for Q4 2019, up 25% quarter-over-quarter.
- 3 funds opened new Xenetic Biosciences positions in Q4 2019 and 2 closed out, a net change of +1 holder.
- The largest Xenetic Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $153K added.
- The largest Xenetic Biosciences seller in Q4 2019 was Sabby Management, an estimated $177K sold.
Based on aggregated 13F filings for Q4 2019.